Latest News
Professor John Tsang and President Peter Salovey discuss the vast possibilities of the Yale-backed Chan Zuckerberg Biohub New York and its ambition to engineer immune cells for early disease prevention, detection, and treatment.
- FEATUREDJanuary 02, 2024Source: Science
The Human Immunome Project (HIP) is an initiative that aims to collect immune data from blood and tissue samples from tens of thousands of people collected at hundreds of collection sites around the world to create the most diverse immune database ever constructed. The collected data will be used to investigate immune system differences across variables such as age, sex, race, diet and socioeconomic levels. The data will also be used to develop AI immune response prediction models. As a proof of concept, HIP will open 7-10 clinics this year, and expects to initiate global collection in 2027.
- FEATUREDNovember 06, 2023Source: Yale Daily News
New Chan Zuckerberg Biohub in New York will connect Yale researchers with counterparts at Columbia University and Rockefeller University to work on engineering immune cells to fight disease.
- May 01, 2024
One of the largest multiomics analyses to date examines hallmarks associated with COVID-19 severity and mortality, and how these factors interact with one another.
- February 07, 2024
Andrew Wang, MD, PhD, discusses the increase in autoimmune and allergic diseases, the effects of the modern environment on our immune system, and how his research can help patients.
- January 23, 2024
The National Academy of Sciences says, "Medzhitov's pioneering contributions have advanced our understanding of the mechanisms of innate immunity, which provides immediate defense against infection."
- November 30, 2023Source: The Atlantic: Dialogues
Answers to big questions about AI from an assembled cast of journalists, technologists, artists, scientists, academics, and more.
- November 01, 2023
Yale has made advances that have changed how doctors and patients grapple with diabetes.
- October 18, 2023
The preservation of insulin-producing beta cells is just one of the benefits of teplizumab, also known as Tzield, a phase 3 trial shows.